Lysostaphin: an enzymatic approach to staphylococcal disease. 3. Combined lysostaphin-methicillin therapy of established staphylococcal abscesses in mice.
Year: 1968
Type: article
Abstract: Serious staphylococcal infections continue to pose therapeutic problems despite the availability of antimicrobial agents that are effective against staphylococci in vitro. Much suggests that this relates, in part, to the nature of the basic lesion in staphylococcal disease. The abscess is the hallmark of staphylococcal disease, and many therapeutic failures appear to result from the inability of available antimicrobials to eliminate staphylococci residing in high titers in abscess lesions. Although antibiotics do penetrate abscess cavities in high concentrations, ' it has been shown that these agents are relatively ineffective against sluggishly multiplying bacteria found in such lesions."8 Lysostaphin is an enzyme containing a peptidase which specifically cleaves the polyglycine bridges unique to the cell walls of Staphylococcus aureus." ' Previous studies from this laboratory have shown that this agent kills coagulase-positive staphylococci regardless of their metabolic state. Further, lysostaphin was highly effective against high titers of coagulasepositive
Source: PubMed Central
Authors: R E Dixon, J S Goodman, M G Koenig
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2273629702